Arbutus Biopharma Corp ABUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABUS is a good fit for your portfolio.
News
-
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
-
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
-
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
-
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
-
Arbutus to Participate in Jefferies Global Healthcare Conference
-
Arbutus to Present Imdusiran Data at EASL Congress 2024
-
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
-
Arbutus to Participate in Two Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $3.92
- Day Range
- $3.86–3.98
- 52-Week Range
- $1.69–3.98
- Bid/Ask
- $3.89 / $3.95
- Market Cap
- $736.00 Mil
- Volume/Avg
- 729,789 / 975,673
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 50.89
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 73
- Website
- http://www.arbutusbio.com
Comparables
Valuation
|
Metric
|
ABUS
|
ICVX
|
ALVR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.13 | 3.30 | 0.75 |
Price/Sales | 50.89 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ABUS
|
ICVX
|
ALVR
|
|---|---|---|---|
Quick Ratio | 6.47 | 17.59 | 18.38 |
Current Ratio | 6.69 | 18.06 | 18.48 |
Interest Coverage | −262.44 | — | — |
Quick Ratio
ABUS
ICVX
ALVR
Profitability
|
Metric
|
ABUS
|
ICVX
|
ALVR
|
|---|---|---|---|
Return on Assets (Normalized) | −39.70% | −29.30% | −52.15% |
Return on Equity (Normalized) | −52.72% | −31.87% | −65.46% |
Return on Invested Capital (Normalized) | −56.43% | −34.69% | −59.04% |
Return on Assets
ABUS
ICVX
ALVR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Kjnzpzmds | Hhyj | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fwghbhw | Gbvrlrg | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gjkjzxx | Lbcgqxh | $118.7 Bil | |||
| Moderna Inc
MRNA
| Nzznrtbgw | Wnlk | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hcltswwz | Gpljgd | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Mnghrzvsd | Hmpt | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Qvbmslpc | Kbxg | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bqhspzsrb | Fpvndb | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Cklgpzd | Ngmr | $15.0 Bil | |||
| Incyte Corp
INCY
| Bftfzfyb | Mmlnvbn | $13.5 Bil |